Loading...

Defence Therapeutics Inc.

DTC.CN•CNQ
Healthcare
Biotechnology
CA$0.60
CA$0.02(3.45%)

Defence Therapeutics Inc. (DTC.CN) Company Profile & Overview

Explore Defence Therapeutics Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Defence Therapeutics Inc. (DTC.CN) Company Profile & Overview

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

SectorHealthcare
IndustryBiotechnology
CEOSebastien Plouffe

Contact Information

https://defencetherapeutics.com
514 947 2272
1680 – 200 Burrard Street, Vancouver, BC, V6C 3L6

Company Facts

5 Employees
IPO DateMay 10, 2021
CountryCA
Actively Trading

Frequently Asked Questions

;